文献速递肾小球疾病急性肾损伤

依库珠单抗联合治疗抗GBM病的疗效与安全性

Efficacy and safety of eculizumab-combined therapy for patients with anti-GBM disease.
PubMed 文献 · Nephrol Dial Transplant · 2026-09-09

这项多中心回顾性队列研究纳入42例表现为急进性肾小球肾炎的抗GBM病患者,比较依库珠单抗联合常规免疫抑制治疗(13例)与未用依库珠单抗的对照(29例)。结果显示依库珠单抗组12周肾脏存活率显著更高(69.2% vs 31.0%,p=0.021),24周数值上更高但未达统计学显著,不良事件无显著差异。

要点

  • 依库珠单抗联合治疗可提高抗GBM病12周肾脏存活率。
  • 24周肾脏存活获益未达统计学显著,需长期随访验证。
  • 联合治疗未显著增加感染或其他不良事件风险。

核心结论

  • 依库珠单抗联合治疗改善抗GBM肾炎12周早期肾脏存活,且未增加不良事件风险。
  • 24周肾脏存活获益仅为数值上更高,需前瞻性大样本长期随访验证疗效与安全性。

研究设计与样本

  • 多中心回顾性队列研究,纳入42例表现为急进性肾小球肾炎的抗GBM病患者。
  • 所有患者接受强化免疫抑制治疗,包括静脉甲泼尼龙冲击后口服泼尼松维持,并联合至少两种以下治疗:静脉环磷酰胺、治疗性血浆分离、利妥昔单抗或依库珠单抗。
  • 依库珠单抗组13例接受依库珠单抗900 mg每周一次、共1-5次,联合其他治疗;对照组29例未接受依库珠单抗。

主要发现

  • 12周肾脏存活率依库珠单抗组显著高于对照组(69.2% vs 31.0%,p=0.021)。
  • 24周肾脏存活率依库珠单抗组数值上更高(66.7% vs 40.7%,p=0.081)。
  • Gehan-Breslow-Wilcoxon检验显示组间肾脏存活差异有统计学意义(χ²=4.137;p=0.042),但log-rank检验未达统计学显著(χ²=3.491;p=0.062)。
  • 感染或其他不良事件总体发生率无显著差异。

关键数值与推荐

  • 依库珠单抗用法:900 mg每周一次,共1-5次。
  • 12周肾脏存活率:依库珠单抗组69.2%,对照组31.0%(p=0.021)。
  • 24周肾脏存活率:依库珠单抗组66.7%,对照组40.7%(p=0.081)。

临床怎么用

  • 对表现为急进性肾小球肾炎的抗GBM病患者,可在强化免疫抑制治疗基础上考虑联合依库珠单抗以改善早期肾脏存活。
  • 联合依库珠单抗未显著增加感染等不良事件,但需关注长期安全性。
  • 24周获益未达统计学显著,临床决策应结合个体情况并期待前瞻性研究证实。

局限性

  • 回顾性队列设计,样本量较小(共42例,依库珠单抗组13例)。
  • 随访时间较短,仅报告12周和24周结局。
  • 依库珠单抗剂量和疗程不一(1-5次),对照组与依库珠单抗组基线可能不可比。
  • 不良事件通过临床和实验室数据 ascertain,可能存在漏报。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The study aimed to evaluate the efficacy and safety of eculizumab in addition to conventional therapy for anti-glomerular basement membrane (anti-GBM) disease presenting rapidly progressive glomerulonephritis (RPGN). METHODS: 42 patients with anti-GBM disease presenting with RPGN were included in this multicenter retrospective cohort study. All patients received intensive immunosuppressive therapy including intravenous methylprednisolone pulses followed by maintenance prednisone, in combination with at least two of the following: intravenous cyclophosphamide, therapeutic plasma apheresis, rituximab, or eculizumab. The cohort was stratified into two groups: the eculizumab group (n = 13) which received eculizumab (900 mg once weekly for 1-5 doses) in combination with other therapies, and the control group (n = 29) which did not receive eculizumab. Kidney survival at 12 weeks and 24 weeks, and adverse events (infections, metabolic alterations, laboratory abnormalities), ascertained via clinical and laboratory data. RESULTS: At 12 weeks, the eculizumab group showed significantly higher kidney survival compared with the control group (69.2% vs. 31.0%, p = 0.021). At 24 weeks, kidney survival remained numerically higher in the eculizumab group (66.7% vs. 40.7%, p = 0.081). Kaplan-Meier curves for renal survival by the Gehan-Breslow-Wilcoxon test, which places greater emphasis on early events, revealed a statistically significant difference between the groups (χ² = 4.137; p = 0.042); however, the difference assessed by the log-rank test did not reach statistical significance (χ² = 3.491; p = 0.062). There were no significant differences in the overall incidence of infections or other adverse events. CONCLUSION: Combined therapy with eculizumab showed improved early kidney survival for anti-GBM nephritis at 12 weeks, and did not increase the risk of adverse events. Prospective, large-sample studies with long-term follow-up are needed to validate its efficacy and safety.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lang X, Hong X, Wu W, et al. Efficacy and safety of eculizumab-combined therapy for patients with anti-GBM disease. Nephrol Dial Transplant. 2026. PMID: 42714831. doi:10.1093/ndt/gfag210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。